Gout Management Guidelines
Acute Management
- For acute gout, choose between corticosteroids, NSAIDs, or colchicine as first-line therapy, with selection based on patient contraindications and cost considerations, as recommended by the American College of Physicians 1
- Low-dose colchicine (1.5 mg total: 1.2 mg initially, then 0.6 mg one hour later) should be used instead of high-dose regimens to minimize gastrointestinal and other adverse effects, according to the American College of Physicians 1
Chronic Management
- Do not initiate urate-lowering therapy after a first gout attack or in patients with infrequent attacks; reserve it for recurrent disease, as recommended by the American College of Physicians 1
- Initiate urate-lowering therapy (ULT) only in patients with recurrent attacks (≥2 per year), tophi, radiographic changes, or uric acid nephrolithiasis, as suggested by the American College of Rheumatology 2
- Allopurinol is first-line therapy: Start at 100 mg daily and increase by 100 mg every 2-4 weeks until serum uric acid reaches <6 mg/dL, maximum 800 mg daily, according to the American College of Rheumatology 2
- Target serum uric acid <6 mg/dL (360 μmol/L) and maintain lifelong, as recommended by the American College of Rheumatology 2
- Mandatory prophylaxis with colchicine or NSAIDs during the first months of urate-lowering therapy prevents paradoxical flares that occur from urate mobilization, according to the American College of Rheumatology 3
- Weight loss (5% BMI reduction) reduces recurrent flare odds by 40% in overweight/obese patients, as suggested by the American Heart Association 3
- Limit alcohol (especially beer and spirits), purine-rich foods (organ meats, shellfish), and high-fructose corn syrup beverages, as recommended by the American Heart Association 3
- Encourage low-fat dairy products which have protective effects, according to the American Heart Association 4
- Regular serum uric acid monitoring is essential to ensure target <6 mg/dL is maintained, as recommended by the American College of Rheumatology 3
Comparison of Gout and Pseudogout Management
| Feature | Gout | Pseudogout |
|---|---|---|
| Acute treatment | NSAIDs/colchicine/corticosteroids [1] | NSAIDs/colchicine/corticosteroids |
| Chronic prevention | Urate-lowering therapy available [2] | No disease-modifying therapy |
| Lifestyle impact | Significant (diet, alcohol, weight) [3] | Minimal to none |
| Monitoring | Serum uric acid targets [3] | No biochemical monitoring needed |
| Long-term prognosis | Controllable with ULT [3] | Recurrent attacks inevitable |